Bergdoll v. Coopersurgical, Inc., 2025 U.S. Dist. LEXIS 38300 (W.D. Mo. March 4, 2025), is an effective Class III medical system preemption determination. The system was a Filshie clip, which is used to carry out tubal ligations. The declare in Bergdoll is the everyday one which the clip migrated and brought about antagonistic signs. Bergdoll can be typical of the development of defendants in Filshie clip litigation doing higher on premarket approval (PMA) preemption on abstract judgment than on a movement to dismiss.
The plaintiffs (spouse and husband) introduced claims for design defect, manufacturing defect, failure to warn, “strict legal responsibility negligence” (no matter that’s), violation of client safety legal guidelines, gross negligence, and punitive damages. The plaintiffs’ most important beef with the defendants appears to be a failure to report antagonistic occasions to the Food and Drug Administration (FDA), leading to an alleged understatement of the price of migration.
Both sides filed abstract judgment motions. The plaintiffs misplaced and the defendants gained. The court docket’s opinion makes clear why that had to be the outcome.
It was undisputed that the FDA reviewed and audited the defendants’ complaint-handling procedures and by no means discovered noncompliance. The plaintiffs claimed that “the FDA doesn’t know in regards to the huge numbers of ‘scientific articles’ and ‘a whole lot of antagonistic occasion studies’ that Defendants have deemed not reportable. In essence, Plaintiffs contend Defendants are failing to report data to the FDA and if the FDA had this data Defendants wouldn’t be present in compliance.”
The plaintiffs had been clearly endeavoring to evade preemption, however they failed. PMA system categorical preemption is triggered when the federal authorities established necessities – which, in fact, it did for the Filshie clips – and the plaintiffs’ claims would impose necessities “which are completely different from, or as well as to the federal ones, and that relate to security and effectiveness.” Check, verify, and verify.
It is a marvel that the plaintiffs even bothered to file a design defect declare. With a category III system, preemption of such claims is iron clad.
The Bergdoll determination would possibly be most useful on preemption of the manufacturing defect declare. That is a reason for motion the place plaintiffs have a tendency to increase essentially the most mud (and by “mud” we imply confusion) over the scope of preemption. The Bergdoll court docket held that to escape preemption of a producing defect declare on abstract judgment, the plaintiff should show that the medical system “was manufactured in a approach that violated the PMA necessities.” Compliance with the manufacturing course of issues. Malfunction by itself doesn’t set up deviation from specs.
Naturally, the plaintiffs tried to avail themselves of the dreaded Riegel parallel declare exception, however, once more, the plaintiffs provided no claims of design or manufacturing deviations from FDA necessities.
The failure to warn claims had been a goner as a result of the defendants’ FDA-approved warnings said the speed of symptomatic migration.
Bergdoll seems to be a state of affairs during which plaintiff lawyer promoting dredged up previous circumstances like this one, the place the insertion was no less than 15 years earlier than swimsuit. Here, the plaintiffs tried to assert a warning defect by the use of failure to report. That failed. The warning language was what the FDA authorized. Anything else would be “completely different from or as well as to.”
The Bergdoll court docket delivered a one-two preemption punch to the plaintiffs’ case, as a result of it additionally held that the failure to report claims amounted to personal FDCA enforcement and had been thus impliedly preempted beneath Buckman.
Further, to the extent the plaintiffs’ principle would require system producers to inform finish customers a few larger migration price, that might counter or complement the FDA requirement to ship antagonistic occasion studies to the FDA solely. The variance that the plaintiffs recognized between the decrease reported migration price and what plaintiffs assert is the precise, larger migration price appears to be that asymptomatic migration claims will not be reportable antagonistic occasions. Fine. That variance will not be the stuff of a product legal responsibility declare, irrespective of the reason for motion. But it’s the stuff of preemption of each reason for motion.
Various different claims, primarily based on negligence and client fraud had been primarily based on the identical information and had been equally preempted.